Transaction details
Ivan Hyep, the chief financial officer of Bicara Therapeutics Inc. (NASDAQ: BCAX), sold 9,200 shares of the company’s common stock on March 23, 2026. The sale generated proceeds of $170,348 based on an average sale price of $18.5161 per share. Reported trade prices on that date ranged between $18.15 and $18.84.
According to a Form 4 filed with the Securities and Exchange Commission, the disposition was carried out under a Rule 10b5-1 trading plan that Hyep adopted on February 13, 2025. The filing also shows that the sale occurred while the stock was trading near its 52-week high of $20.25, after having delivered a roughly 62% return over the prior six months.
Concurrent option exercise
On the same calendar day, Hyep exercised options to acquire 9,200 shares of Bicara Therapeutics common stock at an exercise price of $3.7898 per share, for an aggregate exercise value of $34,866. The exercised options stem from a stock option plan that vests in sixteen equal quarterly installments beginning after April 5, 2023, and the options have an expiration date of April 5, 2033.
Following the sale and the option exercise, Hyep is reported to directly own 145,355 shares of Bicara Therapeutics.
Valuation context and upcoming earnings
Market commentary cited in the filing notes that InvestingPro’s analysis views the shares as slightly overvalued relative to the service’s Fair Value estimate. The company’s next scheduled earnings announcement is March 26, 2026, two days after the reported transactions. The InvestingPro service is noted as offering eight additional tips for BCAX subscribers.
Corporate financing and analyst view
Separately, Bicara Therapeutics recently completed an underwritten public offering that generated approximately $172.5 million in gross proceeds. The company issued 8,581,250 shares of common stock and pre-funded warrants exercisable for 2,200,000 shares. The common shares were priced at $16.00 apiece, while the pre-funded warrants were priced at $15.9999 per warrant and carry an exercise price of $0.0001 per share. The offering included 1,406,250 additional shares sold under the underwriters’ option, which was fully exercised.
Citizens has reaffirmed its Market Outperform rating on Bicara Therapeutics with a price target of $31.00. The firm’s published valuation supporting that target relies on a discounted earnings per share and revenue multiple framework, and Citizens’ analysis incorporated long-term follow-up data that Bicara presented at the 2026 MHNCS conference.
Context for market participants
The sequence of insider sale and option exercise, combined with recent equity issuance and an upcoming earnings release, creates a compact set of corporate financing and insider activity to monitor closely. The facts reported in the SEC filing and the company disclosures provide the concrete transaction figures and timelines that investors and analysts can use as they assess near-term liquidity, dilution from the offering, and forthcoming operational results.
Key facts at a glance
- Sale date: March 23, 2026 - 9,200 shares sold at an average of $18.5161, proceeds $170,348; trade prices ranged $18.15 to $18.84.
- Option exercise: 9,200 options exercised at $3.7898, total $34,866; options vest in 16 equal quarterly installments following April 5, 2023, expire April 5, 2033.
- Share ownership after transactions: 145,355 shares directly held by the CFO.
- Company financing: Underwritten offering raised ~ $172.5 million gross; common stock at $16.00, pre-funded warrants at $15.9999 with $0.0001 exercise price; underwriters’ option fully exercised for 1,406,250 shares.
- Analyst view and data: Citizens maintains Market Outperform and $31 price target; InvestingPro finds shares slightly overvalued versus its Fair Value and offers eight further tips to subscribers.
- Timing: Stock up ~62% over the past six months and trading near a 52-week high of $20.25; company earnings report due March 26, 2026.